Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges | BioInformant Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies — directly applicable to biotech and pharma iPSC programs. Toulouse, 2026 A...

Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges - Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies, directly applicable to biotech & pharma iPSC programs.

bioinformant.com/cell-easy-ip...

RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China | BioInformant Partnership Delivers RoosterBio’s Research-Grade and CliniControlTM cGMP Media Platforms to China’s Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order Fulfillm...

RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China - bioinformant.com/roosterbio-a...

Key Events in the Evolution of iPSC Products that You Need to Know | BioInformant Developing induced pluripotent stem cell (iPSC) products requires a thorough understanding of the evolution of iPSC research advances. Because the cell type was recently discovered in 2006, the follow...

Key Events in the Evolution of iPSC Products that You Need to Know - bioinformant.com/key-events-i...

Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases | BioInformant TAMPA, Fla. and CAMBRIDGE, Mass., March 11, 2026 – GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the developmen...

Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases - bioinformant.com/catalent-and...

Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform | BioInformant Newly licensed intellectual property enables genetic induction of early meiosis, further strengthening Gameto’s best-in-class platform for modeling human ovarian development and disease AUSTIN, Texas,...

Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform - bioinformant.com/gameto-licen...
@harvardmed.bsky.social @wyssinstitute.bsky.social

Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials | BioInformant LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 17, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the safety of allogeneic mesenc...

Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials - bioinformant.com/longevity-me...

Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing | BioInformant Giessen, Germany – 17.03.2026 – Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is i...

Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing - bioinformant.com/green-elepha...

Congrats to the REPROCELL team on launching its new StemEdit Platform, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system.

Read more: bioinformant.com/reprocell-st...

#ipscells #geneediting #ai

Longevity Medical Institute® Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers | BioInformant LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 11, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the therapeutic potential of al...

Longevity Medical Institute® Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers - bioinformant.com/longevity-me... @longevitymedical8.bsky.social

Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease | BioInformant March 11, 2026,  Lexington, MA / United States — Cytonome-ST today congratulated Sumitomo Pharma Co., Ltd. following the company’s announced receipt of regulatory approval for the world’s first iPS ce...

Cytonome Congratulates Sumitomo Pharma on Regulatory Approval for Regenerative Medicine Therapy for Parkinson’s disease - bioinformant.com/cytonome-sum...

10 Biotherapies Books From AABB To Add To Your Reading List In 2026 | BioInformant There is no better time to put together your biotherapies reading list for 2026! In partnership with AABB (Association for the Advancement of Blood C Biotherapies), BioInformant shares 10 must-have te...

10 Biotherapies Books From AABB To Add To Your Reading List In 2026 - bioinformant.com/10-biotherap...

REPROCELL Introduces StemEdit Platform AI-Designed Genome Editors & Hypoimmune iPSC Lines | BioInformant REPROCELL has launched StemEdit, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system. The platform integrates...

REPROCELL Introduces StemEdit Platform: AI-Designed Genome Editors & Hypoimmune iPSC Lines - bioinformant.com/reprocell-st...

@reprocell.bsky.social

World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors | BioInformant Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across multiple models TAICHUNG, Feb. 13, 2026 ...

World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors - bioinformant.com/world-first-...

Longevity Medical Institute® Opens Federally Licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory in Los Cabos | BioInformant LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 3, 2026 — Longevity Medical Institute® today announced the opening of its federally licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory,...

Longevity Medical Institute® Opens Federally Licensed Stem Cell and Regenerative Medicine Biotechnology Laboratory in Los Cabos - bioinformant.com/longevity-me...

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market | BioInformant BOTHELL, Wash. and Cambridge, UK, February 12, 2026 —BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) ma...

BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market - bioinformant.com/biolife-solu...
@qkine.bsky.social @qkinebio.bsky.social

TriHaz Solutions Opens New Chattanooga, Tennessee Facility to Expand Regulated Medical Waste Services Across the Southeast | BioInformant Chattanooga, TN – February 17, 2026 – TriHaz Solutions, a trusted provider of regulated medical waste management, is proud to announce the opening of a new operational facility located at 4120 S Creek...

TriHaz Solutions Opens New Chattanooga, Tennessee Facility to Expand Regulated Medical Waste Services Across the Southeast - bioinformant.com/trihaz-solut...

FDA Grants RMAT to iRegene's NouvNeu001, Making It World's First iPSC Therapy with FTD and RMAT Recognitions | BioInformant Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson’s disease, following compelling Phase I clinical data CHENGDU, China, Jan. 1...

FDA Grants RMAT to iRegene’s NouvNeu001, Making It World’s First iPSC Therapy with FTD and RMAT Recognitions - bioinformant.com/fda-grants-r...

Nucleus Biologics Launches Krakatoa® K500: A Pod-Based, On-Demand Media and Buffer Manufacturing System Transforming Scale Bioproduction | BioInformant Produces 35–500 liters of sterile media and buffers on demand at point-of-use, reducing cost, complexity, and lead times Pod-based, closed single-use system with integrated analytics, QR-code-driven e...

Nucleus Biologics Launches Krakatoa® K500: A Pod-Based, On-Demand Media and Buffer Manufacturing System Transforming Scale Bioproduction - bioinformant.com/nucleus-biol...

I Peace Announces Successful Generation of Human iPS Cells from NKT Cells and Commences Their Availability | BioInformant February 6, 2026 – Palo Alto, CA – Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it has successful...

I Peace Announces Successful Generation of Human iPS Cells from NKT Cells and Commences Their Availability - bioinformant.com/i-peace-anno...

Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience | BioInformant CARLSBAD, Calif. –  Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious m...

Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience - bioinformant.com/lineage-part...
@lineagecell.bsky.social

Cytora, Made Scientific, and Zeo ScientifiX Partner to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in U.S. | BioInformant Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot ...

Cytora, Made Scientific, and Zeo ScientifiX Partner to Manufacture and Commercialize Cytora’s Allogeneic Stem Cell Therapy in U.S. - bioinformant.com/cytora-thera...

Top iPSC Providers Transforming Preclinical Safety for Big Pharma | BioInformant The pharmaceutical industry continues to grapple with preclinical and clinical safety issues, with toxicity remaining a leading cause of drug failure. Cardiovascular toxicity, in particular, stands ou...

Top iPSC Providers Transforming Preclinical Safety for Big Pharma - bioinformant.com/ipsc-derived...
@axolbio.bsky.social @reprocell.bsky.social @insphero.bsky.social

Novo Nordisk Foundation Commits DKK 5.5 Billion to the BioInnovation Institute (BII) through 2035 | BioInformant In a strategic move set to reshape the European biotech and science innovation landscape, the Novo Nordisk Foundation has pledged a long-term investment of up to DKK 5.5 billion (≈ €736 million) to th...

Novo Nordisk Foundation Commits DKK 5.5 Billion to the BioInnovation Institute (BII) through 2035 - bioinformant.com/novo-nordisk...
@novonordisk.bsky.social

Learn how to unlock the link between EV content and function in MSC research. Join RoosterBio Inc. for an insightful webinar, EV Content vs Function: Using Analytical Tools to Reveal the Connection, on Tuesday, February 10th at 11:00 AM ET.

us02web.zoom.us/webinar/regi...

Qkine Limited and Akron Bio Announce Strategic Partnership | BioInformant Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics Cambridge, UK and Boca Raton, FL – January 27, 2026 – Qkine Limited, a lead...

Qkine Limited and Akron Bio Announce Strategic Partnership - bioinformant.com/qkine-and-ak...

Collaboration to Deliver High-Quality Cytokines and Growth Factors to Enable the Advancement of Stem Cell-Based Therapeutics

@qkinebio.bsky.social

CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis | BioInformant Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close...

CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis - bioinformant.com/chu-toulouse...

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia | BioInformant December 08, 2025, Silver Spring, MD (U.S. FDA) — The U.S. Food and Drug Administration announced that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) t...

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia - bioinformant.com/fda-approves...

Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies | BioInformant Belgium, Mont Saint-Guibert, 13 January 2026 – Cellistic, a global leader in allogeneic iPSC-derived cell therapy manufacturing, today announced the launch of three new iPSC-derived GMP cell therapy m...

Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies - bioinformant.com/cellistic-ne...

Xeno-Free RoosterVial™-hDF Available in both 1M or 10M cell per vial formats to meet your needs throughout product development. Trilineage differentiation of a representative XF RoosterVial-hAD lot.

We continue to be awed by RoosterBio’s leadership in cell culture innovation and the way they simplify processes while enabling scalability:

Generate Billions of Xeno-Free Fibroblasts for Your R&D Program:
www.roosterbio.com/products/xen...

WORD+2026 Connecting Global NAM Research. #Bettertogether Organoids, Organ-on-a-Chip, Assembloids and innovative NAMS - bioinformant.com/word2026/

In just three weeks time, the 5th WORD+ event brings together leading researchers, societies and technologies in Cambridge, U.K.